Switch to:
Also traded in: Austria, Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:ISRG's Cash-to-Debt is ranked higher than
98% of the 335 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. NAS:ISRG: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ISRG' s Cash-to-Debt Range Over the Past 10 Years
Min: 12.85  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.86
NAS:ISRG's Equity-to-Asset is ranked higher than
89% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. NAS:ISRG: 0.86 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ISRG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.7  Med: 0.87 Max: 0.9
Current: 0.86
0.7
0.9
Interest Coverage No Debt
NAS:ISRG's Interest Coverage is ranked higher than
97% of the 226 Companies
in the Global Medical Devices industry.

( Industry Median: 73.23 vs. NAS:ISRG: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:ISRG' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 6
Altman Z-Score: 32.15
Beneish M-Score: -2.66
WACC vs ROIC
7.12%
24.71%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 34.40
NAS:ISRG's Operating Margin % is ranked higher than
98% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. NAS:ISRG: 34.40 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ISRG' s Operating Margin % Range Over the Past 10 Years
Min: 25.56  Med: 35.7 Max: 40.3
Current: 34.4
25.56
40.3
Net Margin % 27.99
NAS:ISRG's Net Margin % is ranked higher than
95% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. NAS:ISRG: 27.99 )
Ranked among companies with meaningful Net Margin % only.
NAS:ISRG' s Net Margin % Range Over the Past 10 Years
Min: 19.65  Med: 25.86 Max: 30.14
Current: 27.99
19.65
30.14
ROE % 15.35
NAS:ISRG's ROE % is ranked higher than
82% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. NAS:ISRG: 15.35 )
Ranked among companies with meaningful ROE % only.
NAS:ISRG' s ROE % Range Over the Past 10 Years
Min: 12.17  Med: 18.96 Max: 21.36
Current: 15.35
12.17
21.36
ROA % 13.64
NAS:ISRG's ROA % is ranked higher than
92% of the 336 Companies
in the Global Medical Devices industry.

( Industry Median: 0.33 vs. NAS:ISRG: 13.64 )
Ranked among companies with meaningful ROA % only.
NAS:ISRG' s ROA % Range Over the Past 10 Years
Min: 10.59  Med: 16.51 Max: 18.44
Current: 13.64
10.59
18.44
ROC (Joel Greenblatt) % 159.97
NAS:ISRG's ROC (Joel Greenblatt) % is ranked higher than
97% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: 5.51 vs. NAS:ISRG: 159.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ISRG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 117.99  Med: 186.03 Max: 245.9
Current: 159.97
117.99
245.9
3-Year Revenue Growth Rate 6.80
NAS:ISRG's 3-Year Revenue Growth Rate is ranked higher than
56% of the 243 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. NAS:ISRG: 6.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ISRG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 18.65 Max: 57.1
Current: 6.8
0
57.1
3-Year EBITDA Growth Rate 4.80
NAS:ISRG's 3-Year EBITDA Growth Rate is ranked lower than
51% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 5.60 vs. NAS:ISRG: 4.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ISRG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -62.8  Med: 29.4 Max: 318.7
Current: 4.8
-62.8
318.7
3-Year EPS without NRI Growth Rate 3.80
NAS:ISRG's 3-Year EPS without NRI Growth Rate is ranked higher than
51% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. NAS:ISRG: 3.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ISRG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -61.5  Med: 20.9 Max: 76.8
Current: 3.8
-61.5
76.8
GuruFocus has detected 5 Warning Signs with Intuitive Surgical Inc $NAS:ISRG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ISRG's 30-Y Financials

Financials (Next Earnings Date: 2017-07-20)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3841
Compare:NYSE:BSX, NYSE:ZBH, NYSE:EW, NYSE:STJ, NYSE:SYK, OTCPK:SNNUF, NAS:ALGN, OTCPK:SONVY, NYSE:VAR, NYSE:TFX, OTCPK:CNVVY, OTCPK:SDMHF, OTCPK:CHEOY, OTCPK:WILLF, NAS:ABMD, NAS:MASI, OTCPK:FSPKF, OTCPK:GGNDF, NAS:IART, NAS:NUVA » details
Traded in other countries:ISRG.Austria, IUI1.Germany, ISRG.Switzerland, 0R29.UK,
Headquarter Location:USA
Intuitive Surgical Inc designs, manufactures and markets da Vinci Surgical Systems and related instruments and accessories.

Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. Intuitive Surgical also provides the instrumentation, disposable accessories, and warranty services for the system. The firm has placed roughly 4,000 da Vinci systems in hospitals worldwide, with 2,600 installations in the U.S. and a growing number in emerging markets.

Guru Investment Theses on Intuitive Surgical Inc

Baron Opportunity Fund Comments on Intuitive Surgical - Feb 21, 2017

Intuitive Surgical (NASDAQ:ISRG) manufactures and markets the da Vinci Surgical System, a robotic surgical system consisting of a surgeon’s console, a patient-side cart, a high performance vision system and proprietary “wristed” instruments and surgical accessories. The da Vinci system seamlessly translates the surgeon’s natural hand movements on instrument controls at the console into corresponding micro-movements of instruments inserted into the patient through small puncture incisions or ports. The da Vinci provides the surgeon with the intuitive control, range of motion, fine tissue manipulation capability and 3-D vision characteristics of open surgery, while simultaneously allowing the surgeon to work through the small ports of minimally-invasive surgery. Patients treated with the da Vinci system benefit from improved clinical results, smaller incisions, fewer complications, less blood loss, less nerve damage, reduced pain and faster recovery compared with open surgery. The company is targeting four million annual surgical procedures worldwide and, we believe, this target is likely to increase over time. In 2016, roughly 750,000 procedures were performed using Intuitive’s robotic systems, implying substantial runway for growth.



From Baron Funds' Baron Opportunity Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds' Fifth Avenue Growth Fund Comments on Intuitive Surgical - Feb 13, 2017

After a multi-year hiatus, we re-initiated an investment in Intuitive Surgical, Inc. (NASDAQ:ISRG) Intuitive sells the da Vinci robotic surgical system, which enables surgeons to perform minimally-invasive surgery in a number of different procedure categories. Minimally-invasive surgery benefits patients because they generally experience less pain and faster recovery after the procedure. Intuitive has held an effective monopoly on robotic-assisted surgery for many years. We believe the company has durable competitive advantages consisting of patents, technology, regulatory approvals, a worldwide installed base of systems, large salesforce, and balance sheet with over $4 billion in net cash. Although Intuitive is expected to face competitors in the future, we believe it will be difficult for competitors to displace the company and the company will maintain its leadership position. In 2016, roughly 750,000 procedures were performed worldwide using Intuitive’s robotic systems, an increase of 15% year-over-year. Intuitive generates revenue from instruments/accessories every time a procedure is performed using its robotic system, which together with annual service fees provides recurring revenue. Management has defined its current addressable market as four million procedures, but we believe Intuitive will continue to expand its addressable market by entering new procedure areas. The company has an exciting pipeline of new products, including a single port system that will enable new procedures and a robotic catheter system that will enable lung tissue biopsies to be taken minimally invasively. In the fourth quarter, the stock pulled back despite a strong fundamental outlook because investors became concerned that the repeal of the Affordable Care Act would cause Intuitive’s hospital customers to cut capital spending, which would negatively impact Intuitive’s system sales. We saw this pull-back as short-sighted and bought the stock. We think Intuitive can grow revenue and earnings at attractive rates over the long term.



From Baron Funds' Fifth Avenue Growth Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Intuitive Surgical Inc

Intuitive Surgical Reports New Employee Option Grants for June 2017
5 Companies Reach Yearly Highs Corning, Salesforce among those achieving milestones
According to GuruFocus' list, these stocks have reached their 52-week highs. Read more...
Intuitive Surgical Receives FDA Clearance for Latest da Vinci® Robotic-Assisted Surgical System
Intuitive Surgical Reports New Employee Option Grants for May 2017
Intuitive Surgical Receives CE Mark for Latest da Vinci® Robotic-Assisted Surgical System
Intuitive Surgical Reports New Employee Option Grants for April 2017
Intuitive Surgical Reports New Employee Option Grants for March 2017

SUNNYVALE, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. (NASDAQ:ISRG) today reported that equity awards, approved by the Compensation Committee of the Board of Directors, which consists entirely of Independent Directors, were made to 59 new employees. Pursuant to NASDAQ Marketplace Rule 5635(c)(4), the equity awards were granted under the Intuitive Surgical, Inc. 2009 Commencement Incentive Plan, which the Board of Directors of Intuitive Surgical, Inc. adopted for the granting of equity awards to new employees. In accordance with NASDAQ rules, these grants were made under an equity incentive plan without shareholder approval. NASDAQ rules require a public announcement of equity awards to be made under this type of plan.  59 employees were granted a combination of Restricted Stock Units (RSUs) and Stock Options to purchase an aggregate of 4,730 shares of the Company's common stock; 2,371 of the shares granted were Stock Options and 2,359 of the shares granted were RSUs. Both the RSUs and Stock Options vest over four years.  The Stock Options expire in 10 years assuming continued employment. No officers received any award under this plan. The exercise price for the Stock Options granted is $730.15 which was the closing price of Intuitive Surgical, Inc.'s common stock on the NASDAQ Global Market on March 7, 2017. The Company's policy is to issue RSUs and Stock Option grants to new employees, where equity makes sense, on the fifth business day of every calendar month.
About Intuitive Surgical, Inc. Intuitive Surgical, Inc. (NASDAQ:ISRG), headquartered in Sunnyvale, California, is the global technology leader in robotic-assisted, minimally invasive surgery. Intuitive Surgical develops, manufactures and markets robotic technologies designed to improve clinical outcomes and help patients return more quickly to active and productive lives. The Company's mission is to extend the benefits of minimally invasive surgery to the broadest possible base of patients. Intuitive Surgical - Taking surgery beyond the limits of the human hand™. About the da Vinci® Surgical System The da Vinci® System is a breakthrough surgical platform designed to enable complex surgery using a minimally invasive approach. The da Vinci® System consists of an ergonomic surgeon console, a patient-side cart with four interactive robotic arms, a high-performance vision system and proprietary EndoWrist® instruments. Powered by state-of-the-art robotic and computer technology, the da Vinci® System is designed to scale, filter and seamlessly translate the surgeon's hand movements into more precise movements of the EndoWrist® instruments. The net result is an intuitive interface with breakthrough surgical capabilities. By providing surgeons with superior visualization, enhanced dexterity, greater precision and ergonomic comfort, the da Vinci® Surgical System makes it possible for more surgeons to perform minimally invasive procedures involving complex dissection or reconstruction. This ultimately has the potential to raise the standard of care for complex surgeries, translating into numerous potential patient benefits, including less pain, a shorter recovery and quicker return to normal daily activities. Intuitive®, da Vinci®, da Vinci S®, da Vinci® Si™, InSite® and EndoWrist® are trademarks or registered trademarks of Intuitive Surgical, Inc. For more information, please visit the company's web site at www.intuitivesurgical.com.
CONTACT: Intuitive Surgical, Inc.
Investor Relations
408-523-2161

Read more...
Baron Opportunity Fund Comments on Intuitive Surgical Guru stock highlight
Intuitive Surgical (NASDAQ:ISRG) manufactures and markets the da Vinci Surgical System, a robotic surgical system consisting of a surgeon’s console, a patient-side cart, a high performance vision system and proprietary “wristed” instruments and surgical accessories. The da Vinci system seamlessly translates the surgeon’s natural hand movements on instrument controls at the console into corresponding micro-movements of instruments inserted into the patient through small puncture incisions or ports. The da Vinci provides the surgeon with the intuitive control, range of motion, fine tissue manipulation capability and 3-D vision characteristics of open surgery, while simultaneously allowing the surgeon to work through the small ports of minimally-invasive surgery. Patients treated with the da Vinci system benefit from improved clinical results, smaller incisions, fewer complications, less blood loss, less nerve damage, reduced pain and faster recovery compared with open surgery. The company is targeting four million annual surgical procedures worldwide and, we believe, this target is likely to increase over time. In 2016, roughly 750,000 procedures were performed using Intuitive’s Read more...
Baron Funds' Fifth Avenue Growth Fund Comments on Intuitive Surgical Guru stock highlight
After a multi-year hiatus, we re-initiated an investment in Intuitive Surgical, Inc. (NASDAQ:ISRG) Intuitive sells the da Vinci robotic surgical system, which enables surgeons to perform minimally-invasive surgery in a number of different procedure categories. Minimally-invasive surgery benefits patients because they generally experience less pain and faster recovery after the procedure. Intuitive has held an effective monopoly on robotic-assisted surgery for many years. We believe the company has durable competitive advantages consisting of patents, technology, regulatory approvals, a worldwide installed base of systems, large salesforce, and balance sheet with over $4 billion in net cash. Although Intuitive is expected to face competitors in the future, we believe it will be difficult for competitors to displace the company and the company will maintain its leadership position. In 2016, roughly 750,000 procedures were performed worldwide using Intuitive’s robotic systems, an increase of 15% year-over-year. Intuitive generates revenue from instruments/accessories every time a procedure is performed Read more...
John Hussman’s Top 3 New Holdings Guru releases 4th-quarter 2016 portfolio
John Hussman (Trades, Portfolio), founder, chairman and president of Hussman Strategic Advisors Inc., added 59 new holdings to his portfolio in the final quarter of 2016. His top three new holdings are Dick’s Sporting Goods Inc. (NYSE:DKS), Orbotech Ltd. (NASDAQ:ORBK) and Donaldson Co. Inc. (NYSE:DCI). Read more...

Ratios

vs
industry
vs
history
PE Ratio 47.48
ISRG's PE Ratio is ranked lower than
67% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 31.71 vs. ISRG: 47.48 )
Ranked among companies with meaningful PE Ratio only.
ISRG' s PE Ratio Range Over the Past 10 Years
Min: 17.77  Med: 37.45 Max: 107.2
Current: 47.48
17.77
107.2
Forward PE Ratio 40.16
ISRG's Forward PE Ratio is ranked lower than
78% of the 51 Companies
in the Global Medical Devices industry.

( Industry Median: 25.64 vs. ISRG: 40.16 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 47.48
ISRG's PE Ratio without NRI is ranked lower than
66% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 31.15 vs. ISRG: 47.48 )
Ranked among companies with meaningful PE Ratio without NRI only.
ISRG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 17.77  Med: 37.45 Max: 107.2
Current: 47.48
17.77
107.2
Price-to-Owner-Earnings 45.84
ISRG's Price-to-Owner-Earnings is ranked lower than
64% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 37.27 vs. ISRG: 45.84 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ISRG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 18.18  Med: 40.56 Max: 110.28
Current: 45.84
18.18
110.28
PB Ratio 8.40
ISRG's PB Ratio is ranked lower than
87% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 3.01 vs. ISRG: 8.40 )
Ranked among companies with meaningful PB Ratio only.
ISRG' s PB Ratio Range Over the Past 10 Years
Min: 2.81  Med: 5.98 Max: 15.72
Current: 8.4
2.81
15.72
PS Ratio 13.29
ISRG's PS Ratio is ranked lower than
86% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.36 vs. ISRG: 13.29 )
Ranked among companies with meaningful PS Ratio only.
ISRG' s PS Ratio Range Over the Past 10 Years
Min: 4.15  Med: 9.73 Max: 24.3
Current: 13.29
4.15
24.3
Price-to-Free-Cash-Flow 38.58
ISRG's Price-to-Free-Cash-Flow is ranked lower than
57% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 32.05 vs. ISRG: 38.58 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ISRG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 18.4  Med: 31.27 Max: 94.65
Current: 38.58
18.4
94.65
Price-to-Operating-Cash-Flow 35.01
ISRG's Price-to-Operating-Cash-Flow is ranked lower than
75% of the 136 Companies
in the Global Medical Devices industry.

( Industry Median: 20.50 vs. ISRG: 35.01 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ISRG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.33  Med: 27.26 Max: 84.6
Current: 35.01
11.33
84.6
EV-to-EBIT 34.71
ISRG's EV-to-EBIT is ranked lower than
67% of the 180 Companies
in the Global Medical Devices industry.

( Industry Median: 24.85 vs. ISRG: 34.71 )
Ranked among companies with meaningful EV-to-EBIT only.
ISRG' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.2  Med: 26.4 Max: 74.4
Current: 34.71
10.2
74.4
EV-to-EBITDA 31.70
ISRG's EV-to-EBITDA is ranked lower than
76% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 18.30 vs. ISRG: 31.70 )
Ranked among companies with meaningful EV-to-EBITDA only.
ISRG' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.4  Med: 23.95 Max: 61.9
Current: 31.7
9.4
61.9
PEG Ratio 12.10
ISRG's PEG Ratio is ranked lower than
87% of the 84 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. ISRG: 12.10 )
Ranked among companies with meaningful PEG Ratio only.
ISRG' s PEG Ratio Range Over the Past 10 Years
Min: 0.13  Med: 1.01 Max: 18.01
Current: 12.1
0.13
18.01
Shiller PE Ratio 74.66
ISRG's Shiller PE Ratio is ranked lower than
73% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 47.49 vs. ISRG: 74.66 )
Ranked among companies with meaningful Shiller PE Ratio only.
ISRG' s Shiller PE Ratio Range Over the Past 10 Years
Min: 44.24  Med: 72.08 Max: 4668.5
Current: 74.66
44.24
4668.5
Current Ratio 3.88
ISRG's Current Ratio is ranked higher than
70% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.59 vs. ISRG: 3.88 )
Ranked among companies with meaningful Current Ratio only.
ISRG' s Current Ratio Range Over the Past 10 Years
Min: 2.07  Med: 4.63 Max: 7.43
Current: 3.88
2.07
7.43
Quick Ratio 3.50
ISRG's Quick Ratio is ranked higher than
73% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. ISRG: 3.50 )
Ranked among companies with meaningful Quick Ratio only.
ISRG' s Quick Ratio Range Over the Past 10 Years
Min: 1.72  Med: 4.33 Max: 7.07
Current: 3.5
1.72
7.07
Days Inventory 79.89
ISRG's Days Inventory is ranked higher than
76% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 131.96 vs. ISRG: 79.89 )
Ranked among companies with meaningful Days Inventory only.
ISRG' s Days Inventory Range Over the Past 10 Years
Min: 55.48  Med: 74.23 Max: 91.85
Current: 79.89
55.48
91.85
Days Sales Outstanding 54.13
ISRG's Days Sales Outstanding is ranked higher than
71% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 68.17 vs. ISRG: 54.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
ISRG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.57  Med: 61.96 Max: 79.2
Current: 54.13
48.57
79.2
Days Payable 32.43
ISRG's Days Payable is ranked lower than
76% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 55.39 vs. ISRG: 32.43 )
Ranked among companies with meaningful Days Payable only.
ISRG' s Days Payable Range Over the Past 10 Years
Min: 23.81  Med: 32.39 Max: 58.29
Current: 32.43
23.81
58.29

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.50
ISRG's 3-Year Average Share Buyback Ratio is ranked higher than
74% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: -4.10 vs. ISRG: -0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ISRG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -115.5  Med: -2.1 Max: 2.4
Current: -0.5
-115.5
2.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 44.22
ISRG's Price-to-Net-Cash is ranked lower than
79% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 15.77 vs. ISRG: 44.22 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ISRG' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.88  Med: 20.72 Max: 333.4
Current: 44.22
2.88
333.4
Price-to-Net-Current-Asset-Value 23.32
ISRG's Price-to-Net-Current-Asset-Value is ranked lower than
82% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 6.67 vs. ISRG: 23.32 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ISRG' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.21  Med: 12.24 Max: 28.5
Current: 23.32
2.21
28.5
Price-to-Tangible-Book 9.16
ISRG's Price-to-Tangible-Book is ranked lower than
78% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 3.91 vs. ISRG: 9.16 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ISRG' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.05  Med: 5.95 Max: 16.47
Current: 9.16
2.05
16.47
Price-to-Intrinsic-Value-Projected-FCF 3.14
ISRG's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
64% of the 143 Companies
in the Global Medical Devices industry.

( Industry Median: 2.41 vs. ISRG: 3.14 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ISRG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.45  Med: 2.53 Max: 14.71
Current: 3.14
1.45
14.71
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.67
ISRG's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
61% of the 28 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. ISRG: 1.67 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.37
ISRG's Price-to-Median-PS-Value is ranked lower than
71% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 1.04 vs. ISRG: 1.37 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ISRG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.32  Med: 0.95 Max: 2.16
Current: 1.37
0.32
2.16
Price-to-Graham-Number 4.40
ISRG's Price-to-Graham-Number is ranked lower than
73% of the 142 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. ISRG: 4.40 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ISRG' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.8  Med: 3.52 Max: 8
Current: 4.4
1.8
8
Earnings Yield (Greenblatt) % 2.88
ISRG's Earnings Yield (Greenblatt) % is ranked higher than
64% of the 334 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. ISRG: 2.88 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ISRG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.3  Med: 3.8 Max: 9.8
Current: 2.88
1.3
9.8
Forward Rate of Return (Yacktman) % 4.97
ISRG's Forward Rate of Return (Yacktman) % is ranked lower than
59% of the 127 Companies
in the Global Medical Devices industry.

( Industry Median: 8.76 vs. ISRG: 4.97 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ISRG' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.2  Med: 29.65 Max: 141.9
Current: 4.97
0.2
141.9

More Statistics

Revenue (TTM) (Mil) $2,784.10
EPS (TTM) $ 19.85
Beta0.83
Short Percentage of Float6.95%
52-Week Range $610.71 - 963.54
Shares Outstanding (Mil)36.84

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 2,979 3,338 3,663
EPS ($) 23.61 27.88 29.33
EPS without NRI ($) 23.61 27.88 29.33
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.84%
Dividends per Share ($)
» More Articles for ISRG

Headlines

Articles On GuruFocus.com
Charlie Tian's Interview on The Next Level Show Jun 28 2017 
Paulson Dives Deeper Into Valeant With Increased Holding Jun 27 2017 
US Market Indexes Lower, Technology Stock Volatility a Factor Jun 27 2017 
General Mills to Release 4th-Quarter, Full-Fiscal 2017 Results Jun 27 2017 
Warren Buffett Interprets the State of the Economy on PBS Newshour Jun 27 2017 
Office Space Provider Is a Good Stock to Follow Jun 27 2017 
Don't Lose Your Faith in Cisco Systems Jun 27 2017 
The Future of Value Investing Jun 27 2017 
Quotes From 2 of the World's Greatest Value Investors Jun 27 2017 
Extracts From the Bible of Value Investing Jun 27 2017 

More From Other Websites
Here are the winners and losers in the health-care sector Jun 28 2017
Understanding Competitive Threats For Intuitive Surgical Jun 26 2017
Da Vinci Sp Could Boost ISRG Stock Jun 23 2017
ISRG Expands across Low-Cost Markets with Da Vinci X Launch Jun 23 2017
What Analysts Recommend for Intuitive Surgical Jun 23 2017
Will Intuitive Surgical Stock Witness Continued Growth Momentum? Jun 23 2017
A Robotics ETF Springs To Life Jun 22 2017
3 Stocks That Are Long Overdue for a Split Jun 21 2017
S&P 500 Buybacks Fall 17.5% Year-over-Year to $133.1 Billion for Q1 2017 Jun 21 2017
Which Companies Are Now Outperforming 95% Of All Stocks? Jun 20 2017
Intuitive Surgical Rises As Rivals Fail To Crack DaVinci Code Jun 20 2017
3 Stocks with Huge Competitive Advantages Jun 19 2017
Roundtable: 1 Stock I'm Never Selling Jun 19 2017
Why Does Intuitive Surgical Score as a Strong Buy Right Now Jun 16 2017
Dave & Buster's, Ebix, Siemens, Applied Materials and Intuitive Surgical highlighted as Zacks... Jun 13 2017
How Risky Is Intuitive Surgical Inc.? Jun 13 2017
Cramer revisits a pre-FANG acronym to see if those stocks kept growing Jun 08 2017
Intuitive Surgical Reports New Employee Option Grants for June 2017 Jun 08 2017
A Look Back At When These 5 Stocks Hit $1,000 And Which Issues Could Be There Soon Jun 08 2017
Biotech Movers: NewLink, Inovio, Juno Jun 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}